TL;DR
A combination of biomarker-guided diagnostics with mechanism-based therapies might enable precision medicine approaches and improve clinical outcomes in AD.
The current understanding of the genetic and physiological mechanisms underlying Alzheimer’s disease is reviewed and modern approaches for diagnosis and treatment are discussed.
This review delineates the critical functions of specific miRNAs in orchestrating the three primary pathological pillars of AD: amyloid-β (Aβ) buildup, chronic neuroinflammation, and systemic oxidative stress.
Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...
The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
